Compliance & Validation — Documented
SOC 2 Type II, ISO 27001, GDPR
Enterprise LLM platform with secure private deployment options for regulated life sciences environments.
Cohere provides large language models optimized for enterprise search, summarization, and document intelligence. Their Command and Embed models are deployed in private cloud and on-premise configurations, making them suitable for GxP-sensitive pharma workflows including literature mining, pharmacovigilance signal summarization, and clinical protocol analysis.
100% — Complete coverage. Coverage score — how completely Atlas documents Cohere across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.
SOC 2 Type II, ISO 27001, GDPR
cloud, private cloud, on premise
API consumption / enterprise license
2–4 months
Large Pharma, Top 20 Pharma, CRO / CDMO, IT / Digital, Data Engineer / Architect, Regulatory Affairs, Drug Discovery
Biomarker Discovery, Drug Repurposing, Natural Language Processing, Regulatory Submission Authoring
Series D, $445M raised, 600+ employees, Founded 2019
Not captured in Atlas data — confirm directly. Excluded from the score above.
Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?
Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?
Fujitsu and Cohere announced a strategic partnership — including a Fujitsu investment in Cohere — to jointly develop Takane, an enterprise large language model offered through Fujitsu's platforms with private-environment deployment options for security-conscious industries.
press release (Fujitsu) · 2024-07-16 — Partner: Fujitsu